Urinary tungsten and incident cardiovascular disease in the Strong Heart Study: An interaction with urinary molybdenum

Environmental Research

Volumn 166, Issue , 2018, Pages 444-451

  Nigra, Anne E ^a,b   Howard, Barbara V ^c,d   Umans, Jason G ^c,d   Best, Lyle ^e   Francesconi, Kevin A ^f   Goessler, Walter ^f   Devereux, Richard ^g   Navas Acien, Ana ^a,b  

^a Department of Medicine   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

^d Delaware   (United States)

^e MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^f UNIVERSITY OF GRAZ   (Austria)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

American Indians; Cardiovascular disease; Molybdenum; Strong Heart Study; Tungsten

Indexed keywords

MOLYBDENUM; TUNGSTEN;

CARDIOVASCULAR DISEASE; DISEASE INCIDENCE; DISEASE PREVALENCE; EPIDEMIOLOGY; MOLYBDENUM; MORTALITY; TUNGSTEN; URINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; HEAVY METAL POISONING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINE LEVEL; AMERICAN INDIAN; CROSS-SECTIONAL STUDY; RISK FACTOR; UNITED STATES; URINE;

UNITED STATES;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; MOLYBDENUM; PROSPECTIVE STUDIES; RISK FACTORS; TUNGSTEN; UNITED STATES;

EID: 85048778495     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2018.06.015     Document Type: Article

References (42)

1. Agarwal, S., Zaman, T., Tuzcu, E.M., Kapadia, S.R., Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999–2006. Angiology 62:5 (2011), 422–429.
2. Agency for Toxic Substances and Disease Registry, 2005. Toxicological profile for tungsten.
3. Bolt, A.M., Mann, K.K., Tungsten: an emerging toxicant, alone or in combination. Curr. Environ. Health Rep. 3:4 (2016), 405–415.
4. Brondino, C.D., Romao, M.J., Moura, I., Moura, J.J., Molybdenum and tungsten enzymes: the xanthine oxidase family. Curr. Opin. Chem. Biol. 10:2 (2006), 109–114.
5. Feng, C., Tollin, G., Enemark, J.H., Sulfite oxidizing enzymes. Biochim. Biophys. Acta 1774:5 (2007), 527–539.
6. Fenoglio, I., Corazzari, I., Francia, C., Bodoardo, S., Fubini, B., The oxidation of glutathione by cobalt/tungsten carbide contributes to hard metal-induced oxidative stress. Free Radic. Res. 42:8 (2008), 437–745.
7. George, J., Struthers, A.D., The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther. 26:1 (2008), 59–64.
8. Gondouin, B., Jourde-Chiche, N., Sallee, M., Dou, L., Cerini, C., Loundou, A., et al. Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels. Nephron 131:3 (2015), 167–174.
9. Gotsman, I., Keren, A., Lotan, C., Zwas, D.R., Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J. Card. Fail. 18:9 (2012), 694–701.
10. Grimes, D.J., Ficklin, W.H., Meier, A.L., Mchugh, J.B., Anomalous gold, antimony, arsenic, and tungsten in ground water and alluvium around disseminated gold deposits along the Getchell Trend, Humboldt County, Nevada. J. Geochem. Explor. 52:3 (1995), 351–371.
11. Hays, S.M., Macey, K., Poddalgoda, D., Lu, M., Nong, A., Aylward, L.L., Biomonitoring Equivalents for molybdenum. Regul. Toxicol. Pharmacol. 77 (2016), 223–229.
12. Herken, E.N., Kocamaz, E., Erel, O., Celik, H., Kucukatay, V., Effect of sulfite treatment on total antioxidant capacity, total oxidant status, lipid hydroperoxide, and total free sulfydryl groups contents in normal and sulfite oxidase-deficient rat plasma. Cell Biol. Toxicol. 25:4 (2009), 355–362.
13. Jelikic-Stankov, M., Uskokovic-Markovic, S., Holclajtner-Antunovic, I., Todorovic, M., Djurdjevic, P., Compounds of Mo, V and W in biochemistry and their biomedical activity. J. Trace Elem. Med. Biol. 21:1 (2007), 8–16.
14. Kim, S.C., Schneeweiss, S., Choudhry, N., Liu, J., Glynn, R.J., Solomon, D.H., Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am. J. Med., 128(6), 2015 (653.e7-653.e16).
15. Klaassen, C., Watkins, J.B. III, Casarett & Doull's Essentials of Toxicology. 2015, McGraw Hill Professional.
16. Lasfargues, G., Lison, D., Maldague, P., Lauwerys, R., Comparative study of the acute lung toxicity of pure cobalt powder and cobalt-tungsten carbide mixture in rat. Toxicol. Appl. Pharmacol. 112:1 (1992), 41–50.
17. Lee, E.T., Welty, T.K., Fabsitz, R., Cowan, L.D., Le, N.-A., Oopik, A.J., et al. The Strong heart study: a study of cardiovascular disease in American Indians: design and methods. Am. J. Epidemiol. 132:6 (1990), 1141–1155.
18. Lemus, R., Venezia, C.F., An update to the toxicological profile for water-soluble and sparingly soluble tungsten substances. Crit. Rev. Toxicol. 45:5 (2015), 388–411.
19. Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:9 (2009), 604–612.
20. Lison, D., Human toxicity of cobalt-containing dust and experimental studies on the mechanism of interstitial lung disease (hard metal disease). Crit. Rev. Toxicol. 26:6 (1996), 585–616.
21. Moon, K., Guallar, E., Navas-Acien, A., Arsenic exposure and cardiovascular disease: an updated systematic review. Curr. Atheroscler. Rep. 14:6 (2012), 542–555.
22. Moon, K.A., Guallar, E., Umans, J.G., Devereux, R.B., Best, L.G., Francesconi, K.A., et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease: a prospective cohort study. Ann. Intern. Med. 159:10 (2013), 649–659.
23. Moulin, J.J., Wild, P., Romazini, S., Lasfargues, G., Peltier, A., Bozec, C., et al. Lung cancer risk in hard-metal workers. Am. J. Epidemiol. 148:3 (1998), 241–248.
24. Navas-Acien, A., Silbergeld, E.K., Sharrett, A.R., Calderon-Aranda, E., Selvin, E., Guallar, E., Metals in urine and peripheral arterial disease. Environ. Health Perspect. 113:2 (2004), 164–169.
25. Nigra, A.E., Ruiz-Hernandez, A., Redon, J., Navas-Acien, A., Tellez-Plaza, M., Environmental metals and cardiovascular disease in adults: a systematic review beyond lead and cadmium. Curr. Environ. Health Rep. 3:4 (2016), 416–433.
26. Pang, Y., Peng, R.D., Jones, M.R., Francesconi, K.A., Goessler, W., Howard, B.V., et al. Metal mixtures in urban and rural populations in the US: the Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study. Environ. Res. 147 (2016), 356–364.
27. R Core Team, 2013. R: A language and environment for statistical computing. Vienna, Austria.
28. Scheer, J., Findenig, S., Goessler, W., Francesconi, K.A., Howard, B., Umans, J.G., et al. Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based epidemiological study. Anal. Methods 4:2 (2012), 406–413.
29. Seiler, R.L., Stollenwerk, K.G., Garbarino, J.R., Factors controlling tungsten concentrations in ground water, Carson Desert, Nevada. Appl. Geochem. 20:2 (2005), 423–441.
30. Sheppard, P.R., Bierman, B.J., Rhodes, K., Ridenour, G., Wittel, M.L., Comparison of size and geography of airborne tungsten particles in Fallon, Nevada, and Sweet Home, Oregon, with implications for public health. J. Environ. Public Health, 2012, 509458, 10.1155/2012/50945.
31. Shiue, I., Hristova, K., Higher urinary heavy metal, phthalate and arsenic concentrations accounted for 3-19% of the population attributable risk for high blood pressure: US NHANES, 2009–2012. Hypertens. Res. 37:12 (2014), 1075–1081.
32. Smith D.B., Cannon W.F., Woodruff L.G., Solano F., Ellefsen K.J., 2014. Geochemical and mineralogical maps for soils of the conterminous United States: US Geological Survey; Report No.: 2331–1258.
33. Stoddart, M.L., Jarvis, B., Blake, B., Fabsitz, R.R., Recruitment of American Indians in epidemiologic research: the Strong Heart Study. Am. Indian Alsk. Nativ. Ment. Health Res., 9(3), 2000, 20.
34. Strong Heart Study, 2001. Strong Heart Study Operations Manual. Phase IV. Volume II: Morbidity and Mortality Surveillance Procedures. In.
35. Tani, S., Nagao, K., Hirayama, A., Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clin. Drug Investig. 35:12 (2015), 823–831.
36. Tellez-Plaza, M., Guallar, E., Howard, B.V., Umans, J.G., Francesconi, K.A., Goessler, W., et al. Cadmium exposure and incident cardiovascular disease. Epidemiology 24:3 (2013), 421–429.
37. Tyrrell, J., Galloway, T.S., Abo-Zaid, G., Melzer, D., Depledge, M.H., Osborne, N.J., High urinary tungsten concentration is associated with stroke in the National Health and Nutrition Examination Survey 1999–2010. PLoS One, 8(11), 2013, e77546.
38. US Environmental Protection Agency, 2009. Emerging Contaminant - Tungsten.
39. van der Knaap, M.S., Valk, J., Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency. Magnetic Resonance of Myelination and Myelin Disorders, 2005, 372–376.
40. Welty, T.K., Lee, E.T., Yeh, J., Cowan, L.D., Go, O., Fabsitz, R.R., et al. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. Am. J. Epidemiol. 142:3 (1995), 269–287.
41. Witten, M.L., Sheppard, P.R., Witten, B.L., Tungsten toxicity. Chem. Biol. Interact. 196:3 (2012), 87–88.
42. Yoshida, M., Nakagawa, M., Hosomi, R., Nishiyama, T., Fukunaga, K., Low molybdenum state induced by tungsten as a model of molybdenum deficiency in rats. Biol. Trace Elem. Res. 165:1 (2015), 75–80.